See more : Jiangsu Yangnong Chemical Co., Ltd. (600486.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Canntab Therapeutics Limited (PILL.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Canntab Therapeutics Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Chavant Capital Acquisition Corp. (CLAY) Income Statement Analysis – Financial Results
- Kwong Man Kee Group Limited (8023.HK) Income Statement Analysis – Financial Results
- Altius Renewable Royalties Corp. (ARR.TO) Income Statement Analysis – Financial Results
- MSA Safety Incorporated (MSA) Income Statement Analysis – Financial Results
- Reliance Chemotex Industries Limited (RELCHEMQ.NS) Income Statement Analysis – Financial Results
Canntab Therapeutics Limited (PILL.CN)
About Canntab Therapeutics Limited
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 293.36K | 0.00 | 133.33K | 240.00K | 26.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.16K | 0.00 |
| Cost of Revenue | 0.00 | 223.89K | 546.34K | 0.00 | 96.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 69.47K | -546.34K | 133.33K | 143.61K | 26.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.16K | 0.00 |
| Gross Profit Ratio | 0.00% | 23.68% | 0.00% | 100.00% | 59.84% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 0.00 | 205.03K | 80.36K | 105.75K | 128.14K | 140.73K | 40.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 2.60M | 2.58M | 2.34M | 2.44M | 2.13M | 1.07M | 173.84K | 178.77K | 312.39K | 346.86K | 366.02K | 49.91K |
| Selling & Marketing | 0.00 | 226.39K | 128.18K | 168.51K | 0.00 | 126.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 2.83M | 2.70M | 2.34M | 2.44M | 2.26M | 1.07M | 173.84K | 178.77K | 312.39K | 346.86K | 366.02K | 49.91K |
| Other Expenses | 0.00 | 634.72K | 546.34K | 304.17K | 176.99K | 51.48K | 1.62K | 0.00 | 0.00 | 274.93K | 1.10M | 1.10M | 50.50K |
| Operating Expenses | 0.00 | 3.67M | 3.33M | 2.75M | 2.74M | 2.45M | 1.12M | 173.84K | 178.77K | 587.32K | 1.45M | 1.46M | 100.41K |
| Cost & Expenses | 0.00 | 3.89M | 3.33M | 2.75M | 2.74M | 2.45M | 1.12M | 173.84K | 178.77K | 587.32K | 1.45M | 1.46M | 100.41K |
| Interest Income | 0.00 | 566.67K | 188.72K | 8.46K | 43.19K | 15.01K | 313.00 | 0.00 | 0.00 | 429.00 | 4.51K | 10.16K | 0.00 |
| Interest Expense | 0.00 | 566.67K | 188.72K | 26.58K | 0.00 | 15.01K | 313.00 | 347.68K | -236.00 | 429.00 | 4.51K | 10.16K | -100.41K |
| Depreciation & Amortization | 228.49K | 634.72K | 998.38K | 295.62K | 80.61K | 51.48K | 1.62K | -347.68K | -236.00 | -235.27K | 223.75K | -10.16K | 0.00 |
| EBITDA | 0.00 | -2.96M | -2.78M | -2.32M | -2.42M | -2.37M | -1.11M | -173.84K | -179.00K | -872.97K | -1.33M | -1.45M | -100.41K |
| EBITDA Ratio | 0.00% | -1,009.89% | 0.00% | -1,740.06% | -1,008.82% | -8,894.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,293.36% | 0.00% |
| Operating Income | 0.00 | -3.60M | -3.78M | -2.62M | -2.50M | -2.42M | -1.12M | 173.84K | -178.77K | -637.71K | -1.56M | -1.44M | -100.41K |
| Operating Income Ratio | 0.00% | -1,226.25% | 0.00% | -1,961.77% | -1,042.41% | -9,087.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,193.36% | 0.00% |
| Total Other Income/Expenses | 0.00 | 916.64K | -659.04K | 8.47K | 43.19K | -853.94K | 313.00 | -347.68K | 236.00 | 336.46K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 0.00 | -3.69M | -4.42M | -2.61M | -2.46M | -2.41M | -1.12M | -173.84K | -178.53K | -301.24K | -1.56M | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | -1,257.55% | 0.00% | -1,955.42% | -1,024.41% | -9,031.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -474.83K | 188.72K | -8.46K | -43.19K | -30.02K | -626.00 | 347.68K | -236.00 | -336.89K | -4.51K | -10.16K | 100.41K |
| Net Income | 0.00 | -3.21M | -4.61M | -2.60M | -2.42M | -2.41M | -1.12M | -173.84K | -178.53K | -301.24K | -1.56M | -1.45M | -100.41K |
| Net Income Ratio | 0.00% | -1,095.69% | 0.00% | -1,949.08% | -1,006.42% | -9,031.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,293.36% | 0.00% |
| EPS | 0.00 | -0.09 | -0.13 | -0.10 | -0.10 | -0.11 | -0.07 | -0.75 | -1.18 | -1.53 | -8.30 | -9.38 | -1.65 |
| EPS Diluted | 0.00 | -0.09 | -0.13 | -0.10 | -0.10 | -0.11 | -0.07 | -0.75 | -1.18 | -1.53 | -8.30 | -9.38 | -1.65 |
| Weighted Avg Shares Out | 0.00 | 37.72M | 34.55M | 27.17M | 25.30M | 21.13M | 15.00M | 230.28K | 151.38K | 196.69K | 187.58K | 154.73K | 60.70K |
| Weighted Avg Shares Out (Dil) | 0.00 | 37.72M | 34.55M | 27.17M | 25.30M | 21.13M | 15.00M | 230.28K | 151.38K | 196.69K | 187.58K | 154.73K | 60.70K |
Source: https://incomestatements.info
Category: Stock Reports